Amedisys
Market Cap
US$9.2b
Last Updated
2021/04/19 23:59 UTC
Data Sources
Company Financials +
Executive Summary
Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. More Details
Rewards
Risk Analysis
AMED passed our risk checks.
Snowflake Analysis
Outstanding track record with adequate balance sheet.
Similar Companies
Share Price & News
How has Amedisys's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: AMED is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: AMED's weekly volatility (5%) has been stable over the past year.
Market Performance
7 Day Return
1.5%
AMED
2.7%
US Healthcare
1.3%
US Market
1 Year Return
43.7%
AMED
47.1%
US Healthcare
53.8%
US Market
Return vs Industry: AMED underperformed the US Healthcare industry which returned 47.1% over the past year.
Return vs Market: AMED underperformed the US Market which returned 53.9% over the past year.
Shareholder returns
| AMED | Industry | Market | |
|---|---|---|---|
| 7 Day | 1.5% | 2.7% | 1.3% |
| 30 Day | 4.5% | 3.4% | 5.1% |
| 90 Day | -5.7% | 7.4% | 8.9% |
| 1 Year | 43.7%43.7% | 48.6%47.1% | 56.6%53.8% |
| 3 Year | 317.6%317.6% | 12.6%10.2% | 64.4%53.6% |
| 5 Year | 444.9%444.9% | 19.2%15.2% | 120.4%95.7% |
Long-Term Price Volatility Vs. Market
How volatile is Amedisys's share price compared to the market and industry in the last 5 years?
Simply Wall St News
5 days ago | Simply Wall St
Calculating The Fair Value Of Amedisys, Inc. (NASDAQ:AMED)2 weeks ago | Simply Wall St
Is Amedisys (NASDAQ:AMED) Using Too Much Debt?1 month ago | Simply Wall St
Is Amedisys (NASDAQ:AMED) A Future Multi-bagger?Valuation
Is Amedisys undervalued compared to its fair value and its price relative to the market?
49.83x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: AMED ($282.96) is trading above our estimate of fair value ($204.61)
Significantly Below Fair Value: AMED is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: AMED is poor value based on its PE Ratio (50.2x) compared to the US Healthcare industry average (25.2x).
PE vs Market: AMED is poor value based on its PE Ratio (50.2x) compared to the US market (22.5x).
Price to Earnings Growth Ratio
PEG Ratio: AMED is poor value based on its PEG Ratio (3.8x)
Price to Book Ratio
PB vs Industry: AMED is overvalued based on its PB Ratio (11.5x) compared to the US Healthcare industry average (3.8x).
Future Growth
How is Amedisys forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?
13.3%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AMED's forecast earnings growth (13.3% per year) is above the savings rate (2%).
Earnings vs Market: AMED's earnings (13.3% per year) are forecast to grow slower than the US market (18% per year).
High Growth Earnings: AMED's earnings are forecast to grow, but not significantly.
Revenue vs Market: AMED's revenue (8.9% per year) is forecast to grow slower than the US market (9.3% per year).
High Growth Revenue: AMED's revenue (8.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AMED's Return on Equity is forecast to be low in 3 years time (18.8%).
Past Performance
How has Amedisys performed over the past 5 years?
38.0%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AMED has high quality earnings.
Growing Profit Margin: AMED's current net profit margins (8.9%) are higher than last year (6.5%).
Past Earnings Growth Analysis
Earnings Trend: AMED has become profitable over the past 5 years, growing earnings by 38% per year.
Accelerating Growth: AMED's earnings growth over the past year (44.8%) exceeds its 5-year average (38% per year).
Earnings vs Industry: AMED earnings growth over the past year (44.8%) exceeded the Healthcare industry 23.6%.
Return on Equity
High ROE: AMED's Return on Equity (22.8%) is considered high.
Financial Health
How is Amedisys's financial position?
Financial Position Analysis
Short Term Liabilities: AMED's short term assets ($362.0M) do not cover its short term liabilities ($456.3M).
Long Term Liabilities: AMED's short term assets ($362.0M) exceed its long term liabilities ($300.1M).
Debt to Equity History and Analysis
Debt Level: AMED's debt to equity ratio (26.2%) is considered satisfactory.
Reducing Debt: AMED's debt to equity ratio has increased from 23.6% to 26.2% over the past 5 years.
Debt Coverage: AMED's debt is well covered by operating cash flow (136%).
Interest Coverage: AMED's interest payments on its debt are well covered by EBIT (19.9x coverage).
Balance Sheet
Dividend
What is Amedisys's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AMED's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AMED's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AMED's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AMED's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AMED's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.5yrs
Average management tenure
CEO
Paul Kusserow (59 yo)
6.33yrs
Tenure
US$12,835,547
Compensation
Mr. Paul Berthold Kusserow has been the Chief Executive Officer of Amedisys, Inc since December 16, 2014 and served as its President since December 16, 2014 until February 18, 2021. He serves as Chairman a...
CEO Compensation Analysis
Compensation vs Market: Paul's total compensation ($USD12.84M) is above average for companies of similar size in the US market ($USD6.51M).
Compensation vs Earnings: Paul's compensation has increased by more than 20% in the past year.
Leadership Team
Experienced Management: AMED's management team is considered experienced (3.5 years average tenure).
Board Members
Experienced Board: AMED's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: AMED insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Amedisys, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Amedisys, Inc.
- Ticker: AMED
- Exchange: NasdaqGS
- Founded: 1982
- Industry: Health Care Services
- Sector: Healthcare
- Market Cap: US$9.231b
- Shares outstanding: 32.85m
- Website: https://www.amedisys.com
Number of Employees
Location
- Amedisys, Inc.
- 3854 American Way
- Suite A
- Baton Rouge
- Louisiana
- 70816
- United States
Listings
Biography
Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offer...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/04/19 23:59 |
| End of Day Share Price | 2021/04/19 00:00 |
| Earnings | 2020/12/31 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.